Research programme: chronic pain therapies - Apricus Biosciences

Drug Profile

Research programme: chronic pain therapies - Apricus Biosciences

Alternative Names: Lidocaine - Apricus Biosciences; Lidocaine/prilocaine - Apricus Biosciences; NM 30088

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator NexMed
  • Developer Apricus Biosciences
  • Class
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Pain

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Pain in USA (Topical, Gel)
  • 11 Sep 2010 NexMed is now called Apricus Biosciences
  • 10 Sep 2010 Preclinical trials in Pain in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top